Spermosens is going public
First day of trading expected on may 5th.
Subscription period
March 25th – April 12th, 2021
Introducing Spermosens
Developer of revolutionizing medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments Subscription takes place from the 25th of March through the 12th of April, 2021 before listing on the Spotlight Stock Market with preliminary first trading day on the 5th of May, 2021.
The World Health Organization has identified infertility as a global health issue, affecting approximately 15 percent of the global population in the fertile age group. This is equal to around 60 million couples, being impacted by infertility. In half of the cases, the cause of infertility is the male factor. Spermosens is developing a revolutionizing technology for male fertility diagnostics and fertility treatment.
JUNO-Checked
With Spermosens first product, JUNO- Checked, it will – for the first time – be possible to determine a sperms ability to fertilize the egg cell. This in turn enables the IVF clinic to choose the appropriate fertilization treatment. Today, around 85 percent of IVF treatments fail. Being able to determine the sperm’s ability to fertilize the egg cell is expected to cause to a reduction in the number of IVF-treatments. This leads to:
- Reduced waiting period for childless couples
- Less negative phycological effects
- Reduced cost for the couples in treatment
- Reduced need for hormonal treatments of the female
- Increased capacity of each IVF clinic
- Improved financial outlook for IVF clinics
”We estimate the global sales potential to be around five billion SEK per year, assuming that all of the 3,600 clinics, which we have identified as potential clients, make use of JUNO-Checked for all of their IVF treatments. We won’t be able to reach the entirety of the global market at once, but with our unique product offering and competitive edge, I predict that we will be able to capture a very high market share”.
John Lempert, CEO
Introduction to the stock market
Spermosens AB (publ) is approved for listing on Spotlight Stockmarket and are expected to be listed in May 2021. The share will be traded under the ticker SPERM and ISIN-code SE0015346424.
Spotlight is an alternative market and does not have the same legal status as regulated market. Companies at Spotlight Stockmarket are subject to the rules of Spotlight and not the legal requirements for admission to trading on a regulated market. An investment in a company that is traded on Spotlight Stockmarket is riskier than an investment in a company that is traded on a regulated market.
The share capital, before the issue, amounts to SEK 523,800 divided between 5,238,000 shares on only one class. All shares have a quotient value of SEK 0.10 and confer entitlement to one vote at the General Meeting.
If you have any questions relating to the IPO, please contact Kristoffer Lippert, Gemstone Capital at +45 27 85 54 44 or kl@gemstonecapital.com
Resumé of the issue
Investor events
Investor presentation
CEO Interview
Podcast with Spermosens’ CEO
Digitala Aktiekvällen
Presentation and Q&A
Interview with Spermosens’ CEO
Pressreleases
IPO Calendar
| Date | Activity |
|---|---|
| 23.03.2021 | Memorandum is published |
| 25.03.2021 | First day of public subscription period |
| 12.04.2021 | Last day of public subscription period |
| 13.04.2021 | Result of public subscription is announced |
| 05.05.2021 | Preliminary first day of trading on Spotlight |
Financial reports
2020
Annual report
Extraordinary General Meeting
2019
Shareholders
| Shareholder | Number of shares | Percentage |
|---|---|---|
| Kushagr Punyani | 1 578 240 | 30,1 % |
| Sudha Srivastava | 690 000 | 13,2 % |
| Johan Källstrand | 345 000 | 6,6 % |
| Bertil Lindkvist | 300 000 | 5,7 % |
| Emilie Hultin Takwa | 300 000 | 5,7 % |
| Ecozyme AB | 240 000 | 4,6 % |
| Göran Ofsén | 171 000 | 3,3 % |
| Mohamad Takwa | 147 000 | 2,8 % |
| Paginera Invest AB | 123 000 | 2,3 % |
| Peter Nilsson | 108 000 | 2,1 % |
| John Moll | 108 000 | 2,1 % |
| Other shareholders (31) | 1 127 760 | 21,5 % |
| Total | 5 238 000 | 100,0 % |
Pre subscription
| Name | Bridge loan | Pre subscription | Total amount incl. premium |
|---|---|---|---|
| Polynom Investment AB | 1 578 865 | 1 578 865 | |
| Jens Erik Martin Olsson | 500 000 | 777 873 | 1 302 873 |
| Jimmie Landerman | 1 265 541 | 1 265 541 | |
| SML Holding APS | 952 217 | 952 217 | |
| Christian Månsson | 250 000 | 442 279 | 704 779 |
| Öresund Growth Partner AB | 500 000 | 151 911 | 676 911 |
| Fredrik Åhlander | 500 000 | 106 312 | 631 312 |
| Mikael Blihagen | 625 962 | 625 962 | |
| Henrik Andreasson | 400 000 | 121 529 | 541 529 |
| Jan Richardsson | 400 000 | 420 000 | |
| Other pre subscribers (28) | 2 450 000 | 2 727 511 | 5 300 011 |
Board of Directors
Eva Nilsagård
Chairman of the board
Board member since: 2020
Born: 1964
Main occupation: Board professional
Shares: None
Options: 81 000 direct
Eva Nilsagård is currently the founder and CEO of Nilsagård Consulting AB. Eva holds an executive MBA in business management and organization as well as a master’s degree in accounting and finance from the Gothenburg School of Economics. Eva has been CFO at OptiGroup, Vitrolife and Plastal, SVP Strategy & Business development at Volvo Group and held senior positions in finance and business development at Volvo, AstraZeneca and SKF. Eva has a long experience of listed companies and over 10 years of experience as a mentor for young female managers.
Other current assignments: Nimbus Group AB, board member. Hansa Biopharma AB (publ), board member. Xbrane Biopharma AB, board member. Aktiebolaget Svensk Exportkredit, board member. IRRAS AB, board member. Addlife AB, board member. Bufab AB (publ), board member. Nilsagård Consulting AB, board member and CEO.
Ingela Liljeqvist Soltic
Board member
Board member since: 2019
Born: 1967
Main occupation: Embryologist and Unit Manager, Laboratory, Reproductive Medicine Centre, Skåne University Hospital
Shares: None
Options: None
Dr. Ingela Liljeqvist Soltic currently works as an embryologist and unit manager for laboratory and tissue establishment at the Center for Reproductive Medicine (RMC) at Skåne University Hospital. Ingela has a BSc in Biomedical Laboratory Technology from Lund University and a PhD in Biomedical Science.Ingela has previously worked as an embryologist at IVF Clinic Cura Öresund and at the pharmaceutical company Merck. Ingela has extensive experience from IVF and fertility issues.
John Moll
Board member
Board member since: 2020
Born: 1978
Main occupation: Investor and entrepreneur
Shares: 156,000 direct and via company
Options: None
John Moll is the founder of Torna Kapital AB, through which he invests in development companies. John has conducted studies in finance at Lund University and master´s studies in biotechnology at Lund University. John has a long experience as an entrepreneur and has founded and sold two companies, including in the health and pharmaceutical sector. As an experienced Lund-based investor, John has a wide network of contacts in the Öresund region.
Other current assignments: Aktiebolaget Lundgren, Nilsson & Moll, board member. Carbiotix AB (publ), board member. Qlife Holding AB (publ), board member. Qlife Aps, board member. Huskvarna Stadshotell AB, board member. Town&Country Resorts AB, board member. Acantor Holding AB, board member. Torna Kapital AB, board member.
Sören Melsing Frederiksen
Board member
Board member since: 2020
Born: 1976
Main occupation: VP Sales & Marketing Galenica AB
Shares: 51 000 via company
Options: 27 000 direct
Sören Melsing Frederiksen currently holds the position of Vice President, Generics and Commercial Rx, ORIFARM GROUP A/S. Søren holds a B.A.Sc in Applied Science and a master´s degree in drug development. Søren has held several positions within LEO Pharma and as commercial manager for the Nordic region at Aspen Pharma. Søren has extensive experience in marketing and sales as well as the entire value chain in the pharmaceutical industry.
Other current assignments: VBM Ejendomsselkabet af 2007 Aps, board member. BotSupply ApS, board member. StenoCare A/S, board member. SML Holding ApS, board member and CEO. VBM LaboratorietA/S, board member.
Kushagr Punyani
Board member
Board member since: 2018
Born: 1991
Main occupation: CSO Spermosens AB
Shares: 1 578 240 direct
Options: None
Kushagr Punyani is founder and CSO for Spermosens AB. Kushagr holds a licentiate degree in engineering, microfluidic technology, from Lund University. From his studies in India together with Professor Sudha Srivastava, Punyani laid the foundation for Spermosens’ technology. Kushagr has also been involved in founding a number of companies that develop new technologies in medtech / pharmaceuticals.
Other current assignments: Diagonal Pharma AB, board member. Punyani Labs AB, board member.
Auditors
At the Extraordinary General Meeting MAZARS AB was elected as auditor for Spermosens until the next Annual General Meeting.
Authorized Public Accountant (auktoriserad revisor) Bengt Ekenberg (born 1960) is the auditor in charge.
Management
John Lempert
CEO
Born: 1953
Shares: 104 760 direct
Options: 162 000 direct
John Lempert studied law at Lund University and is by the National Board of Health and Welfare a certified dental technician. John has among other worked for Johnson & Johnson in international positions and in smaller entrepreneurial companies being responsible for developing new patented dental materials from development, through regulatory affairs and manufacturing to completed market entry and build-up.
John has also had assignments for the World Band and has more than 35 years of experience from business development in the medtech industry.
Cajsa Wramdemark
CFO
Born: 1977
Shares: Inga
Options: Inga
Cajsa Wramdemark, owner and founder of More than Finance AB, holds a Master of Science in International Business Administration and Economics from the School of Economics and Management, Lund University.
Cajsa has more than 20 years of experience within finance in both multi-national as well as SME companies within Life Science as well as other areas. She has had roles as CFO and Chief Accounting Manager. In addition to finance, Cajsa has been responsible for HR and Purchasing in previous roles.
FAQ
What is a unit?
A unit consists of (1) new share and (1) free of charge warrant (TO1).
How does it work?
Subscription of units happens during the public subscription period between march 25th and April 12th, 2021. For 5,63 SEK the subscriber gets (1) unit.
What does warrant entail?
A subscription option gives the shareholder a right (but not obligation) to subscribe for newly issued shares in the company, expected in the middle of 2022, at a price equal to 30% discount of the market price at the time of exercise.
Can you trade the warrants?
Given the approval from Spotlight, the warrants will be a separately traded instrument, exactly like a normal stock, traded on Spotlight.
Investor Relations
John Lempert
CEO, Spermosens AB
Lund, Sweden
Tel: +46 76 311 40 91
jsl@spermosens.com
Issuing Bank
Eminova Fondkommission AB
Biblioteksgatan 3, 3 tr.
111 46 Stockholm
Tel: +46 8 684 211 00
info@eminova.se
